Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity

References

• WHO. Hepatitis B vaccines: WHO position paper – recommendations. Vaccine28, 589–590 (2010).
   PubMed Web of Science ®Google Scholar
• Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol.34, 1329–1339 (2005).
   PubMed Web of Science ®Google Scholar
• Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin. Infect. Dis.20, 992–1000 (1995).
   PubMed Web of Science ®Google Scholar
• Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull. World Health Organ.66, 443–455 (1988).
   PubMed Web of Science ®Google Scholar
• Expanded programme on immunization. Global advisory group – part I. Wkly Epidemiol. Rec.67, 11–15 (1992).
   PubMedGoogle Scholar
• Kane MA, Brooks A. New immunization initiatives and progress toward the global control of hepatitis B. Curr. Opin. Infect. Dis.15, 465–469 (2002).
   PubMed Web of Science ®Google Scholar
• Arístegui J, Usonis V, Coovadia H et al. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int. J. Infect. Dis.7, 143–151 (2003).
   PubMedGoogle Scholar
• WHO Department of Immunization, Vaccines and Biologicals. World Health Organization (WHO) vaccine-preventable diseases: monitoring system. 2009 global summary. WHO, Geneva, Switzerland (2009).
   Google Scholar
• Hung HF, Chen THH. Probabilistic cost–effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and hepatitis B e antigen positive prevalence. Vaccine.27, 6770–6776 (2009).
   PubMed Web of Science ®Google Scholar
• MacIntyre CR. Hepatitis B vaccine: risks and benefits of universal neonatal vaccination. J. Paediatr. Child Health37, 215–217 (2001).
   PubMed Web of Science ®Google Scholar
• Hollinger FB. Comprehensive control (or elimination) of hepatitis B virus transmission in the United States. Gut38(Suppl. 2), S24–S30 (1996).
   Google Scholar
• Krahn M, Detsky AS. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost–effectiveness analysis. Med. Decis. Making13, 4–20 (1993).
   PubMed Web of Science ®Google Scholar
• Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine26, 6266–6273 (2008).
   PubMed Web of Science ®Google Scholar
• Purdy MA, Talekar G, Swenson P, Araujo A, Fields H. A new algorithm for deduction of hepatitis B surface antigen subtype determinants from the amino acid sequence. Intervirology50, 45–51 (2007).
   PubMed Web of Science ®Google Scholar
• Okamoto H, Tsuda F, Sakugawa H et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J. Gen. Virol.69, 2575–2583 (1988).
   PubMed Web of Science ®Google Scholar
• Hauser P, Voet P, Simoen E et al. Immunological properties of recombinant HBsAg produced in yeast. Postgrad. Med. J.63(Suppl. 2), S83–S91 (1987).
   PubMed Web of Science ®Google Scholar
• Shokrgozar MA, Shokri F. Subtype specificity of anti-HBs antibodies produced by human B-cell lines isolated from normal individuals vaccinated with recombinant hepatitis B vaccine. Vaccine20, 2215–2220 (2002).
   PubMed Web of Science ®Google Scholar
• Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol. Res.40, 14–30 (2010).
   PubMed Web of Science ®Google Scholar
• Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin. Liver Dis.14, 1–21 (2010).
   PubMedGoogle Scholar
• Yu H, Yuan Q, Ge SX et al. Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype “I”. PLoS One5, e9297 (2010).
   Web of Science ®Google Scholar
• Jutavijittum P, Olinger C, Hubschen J, Yousukh A, Smountry B, Thammavong T. Molecular phylogeny of hepatitis B virus in Laos reveals multiple subtypes of endemic genotypes, numerous unclassifiable strains and a growing prevalence of recombinations within sub- and genotypes and a potential new genotype. Proceedings of the Molecular Biology of Hepatitis B Viruses. Rome, Italy, 16–20 September 2007.
   Google Scholar
• Tran TTH, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. J. Virol.82, 5657–5663 (2008).
   PubMed Web of Science ®Google Scholar
• Tatematsu K, Tanaka Y, Kurbanov F et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J. Virol.83, 10538–10547 (2009).
   PubMed Web of Science ®Google Scholar
• Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J. Viral Hepat.12, 456–464 (2005).
   PubMed Web of Science ®Google Scholar
• Stramer SL, Wend U, Candotti D et al. Nucleic acid testing to detect HBV infection in blood donors. N. Engl. J. Med.364, 236–247 (2011).
   PubMed Web of Science ®Google Scholar
• Miller W. Serological assays. In: Hepatitis B Vaccines in Clinical Practice. Ellis RW, (Ed.). Marcel Dekker, NY, USA, 121–140 (1993).
   Google Scholar
• Kim SH, Shin YW, Hong KW et al. Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees. Antiviral Res.79, 188–191 (2008).
   PubMed Web of Science ®Google Scholar
• Iwarson S, Tabor E, Thomas HC et al. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee. J. Med. Virol.16, 89–96 (1985).
   PubMed Web of Science ®Google Scholar
• Schellekens H, de Reus A, Peetermans JH, van Eerd PA. The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitis B surface antigen. Postgrad. Med. J.63(Suppl. 2), 93–96 (1987).
   PubMed Web of Science ®Google Scholar
• Chan C, Lee S, Lo K. Legend of hepatitis B vaccination: the Taiwan experience. J. Gastroenterol. Hepatol.19, 121–126 (2004).
   PubMed Web of Science ®Google Scholar
• Wen WH, Chen HL, Ni YH et al. Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology53, 429–436 (2011).
   PubMed Web of Science ®Google Scholar
• Chang MH, You SL, Chen CJL et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst.101, 1348–1355 (2009).
   PubMed Web of Science ®Google Scholar
• Chen HL, Chang MH, Ni YH et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA276, 906–908 (1996).
   PubMed Web of Science ®Google Scholar
• Chongsrisawat V, Yoocharoen P, Theamboonlers AT et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop. Med. Int. Health11, 1496–1502 (2006).
   PubMed Web of Science ®Google Scholar
• Wichajarn K, Kosalaraksa P, Wiangnon S. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac. J. Cancer Prev.9, 507–509 (2008).
   PubMedGoogle Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J. Viral Hepat.18, 369–375 (2011).
   PubMed Web of Science ®Google Scholar
• Dong Y, Liu SL, Zhai XJ et al. A serological and molecular survey of hepatitis B in children 15 years after inception of the national hepatitis B vaccination program in eastern China. J. Med. Virol.81, 1517–1524 (2009).
   PubMed Web of Science ®Google Scholar
• Liang X, Bi S, Yang W et al. Epidemiological serosurvey of hepatitis B in China – declining HBV prevalence due to hepatitis B vaccination. Vaccine27, 6550–6557 (2009).
   PubMed Web of Science ®Google Scholar
• Liang X, Bi S, Yang W et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J. Infect. Dis.200, 39–47 (2009).
   PubMed Web of Science ®Google Scholar
• Viviani S, Jack A, Hall AJ et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine17, 2946–2950 (1999).
   PubMed Web of Science ®Google Scholar
• Kimbi GC, Kramvis A, Kew MC. Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. J. Gen. Virol.85, 1211–1220 (2004).
   PubMed Web of Science ®Google Scholar
• Bhimma R, Coovadia HM, Adhikari M, Connolly CA. The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy. Arch. Pediatr. Adolesc. Med.157, 1025–1030 (2003).
   PubMedGoogle Scholar
• Tacke F, Amini-Bavil-Olyaee S, Heim A, Luedde T, Manns MP, Trautwein C. Acute hepatitis B virus infection by genotype F despite successful vaccination in an immune-competent German patient. J. Clin. Virol.38, 353–357 (2007).
   PubMed Web of Science ®Google Scholar
• O’Halloran JA, De Gascun CF, Dunford L et al. Hepatitis B virus vaccine failure resulting in chronic hepatitis B infection. J. Clin. Virol.52(2), 151–154 (2011).
   PubMed Web of Science ®Google Scholar
• Ramírez Albajés V, González Griego A, Almeida Varela R et al. Effectividad absoluta y relativa de la vacunación antihepatitis B en niños de quillabamba, perú, 1997–1999. Rev.Cubana. Invest. Biomed.19, 82–88 (2000).
   Google Scholar
• Duarte MC, Cardona N, Poblete F et al. A comparative epidemiological study of hepatitis B and hepatitis D virus infections in Yanomami and Piaroa Amerindians of Amazonas State, Venezuela. Trop. Med. Int. Health15, 924–933 (2010).
   PubMed Web of Science ®Google Scholar
• Nunes HM, Monteiro MR, Soares M do CP. [Prevalence of hepatitis B and D serological markers in the Parakanã, Apyterewa Indian Reservation, Pará State, Brazil.] Cad. Saude Publica23, 2756–2766 (2007).
   PubMed Web of Science ®Google Scholar
• Venegas M, Alvarado-Mora MV, Villanueva RA et al. Phylogenetic analysis of hepatitis B virus genotype F complete genome sequences from Chilean patients with chronic infection. J. Med. Virol.83, 1530–1536 (2011).
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Bulkow LR, Singleton RJ et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology doi:10.1002/hep.24442 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis – United States, 2007. MMWR Surveill. Summ.58, 1–27 (2009).
   PubMedGoogle Scholar
• Inui A, Komatsu H, Sogo T, Nagai T, Ade K, Fujisawa T. Hepatitis B virus genotypes in children and adolescents in Japan: before and after immunization for the prevention of mother to infant transmission of Hepatitis B virus. J. Med. Virol.79, 670–675 (2007).
   PubMed Web of Science ®Google Scholar
• Yu MW, Yeh SH, Chen PJ et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl Cancer Inst.97, 265–272 (2005).
   PubMed Web of Science ®Google Scholar
• Ocana S, Casas ML, Buhigas I, Lledo JL. Diagnostic strategy for occult hepatitis B virus infection. World J. Gastroenterol.17, 1553–1557 (2011).
   PubMed Web of Science ®Google Scholar
• Gutiérrez-García ML, Fernandez-Rodriguez CM, Lledo-Navarro JL, Buhigas-Garcia I. Prevalence of occult hepatitis B virus infection. World J. Gastroenterol.17, 1538–1542 (2011).
   PubMed Web of Science ®Google Scholar
• Romero M, Madejón A, Fernández-Rodríguez C, García-Samaniego J. Clinical significance of occult hepatitis B virus infection. World J. Gastroenterol.17, 1549–1552 (2011).
   PubMed Web of Science ®Google Scholar
• Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost–effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion43, 721–729 (2003).
   PubMed Web of Science ®Google Scholar